Taisho said to near $1.6 billion deal for Bristol-Myers"s UPSA: Bloomberg

Bristol-Myers Squibb shareholders need convincing on the $74 billion deal for Celgene, but there is a sound logic, writes Charley Grant of WSJ’s ‘Heard on the Street’.....»»

Bristol-Myers Squibb Co., which has held a major presence in the Tampa Bay area since 2014, has entered into a $74 billion merger agreement to acquire a New Jersey biotechnology company. Under terms of the agreement, Celgene Corp. (NASDAQ: CELG) .....»»

Bristol-Myers Squibb Co said on Thursday it would buy Celgene Corp for about $74 billion, creating one of the biggest pharmaceutical companies and combining two significant cancer drug businesses......»»

The cost to insure Bristol-Myers Squibb debt hit its highest point since 2010 on Thursday, following the announcement that the U.S. pharmaceutical company would acquire rival Celgene Corp in a deal worth $74 billion......»»

The cost to insure Bristol-Myers Squibb debt hit its highest point since May 2010 on Thursday, following the announcement that the U.S. pharmaceutical company would acquire rival Celgene Corp in a deal worth about $74 billion......»»

Pharmaceutical giants enter first major deal of 2019Related Stocks: BMY, CELG,.....»»

Bristol-Myers Squibb Co said on Thursday it would buy Celgene Corp for about $74 billion, combining two of the world's largest cancer drug businesses in the biggest pharmaceutical deal ever......»»

Manhattan-based Bristol-Myers Squibb is buying fellow drugmaker Celgene in a cash and stock deal valued at $74 billion, with Bristol-Myers’ shareholders expected to own 69% of the combined entity. ["> To view the full story, click the title link......»»

Manhattan-based Bristol-Myers Squibb is buying fellow drugmaker Celgene in a cash and stock deal valued at $74 billion, with Bristol-Myers’ shareholders expected to own 69% of the combined entity.... To view the full story, click the title link......»»

With Celgene stock trading 25% higher after Bristol-Myers Squibb made a $74 billion acquisition offer, Celgene investors probably shouldn’t wait around to see if the deal closes......»»

Celgene Corp and Bristol-Myers Squibb Co will have to pay $2.2 billion if either of the drugmakers walks away from their $74 billion merger announced on Thursday, according to a regulatory filing......»»

Biotech deal flow is continuing in the new year following Thursday's announcement of Bristol-Myers Squibb Co (NYSE: BMY)'s proposed $74-billion acquisition read more.....»»

Celgene Corp. , the biopharmaceutical company that agreed last week to be acquired by Bristol-Myers Squibb Co. in a mega-deal valued at $74 billion, provided 2019 profit and sales outlooks that were above expectations. The company said it expects a.....»»

Activist hedge fund Starboard Value LP has asked a proxy solicitor to probe the level of support among Bristol-Myers Squibb Co shareholders for the U.S. drug maker's $74 billion deal to buy Celgene Corp, people familiar with the matter said on Friday......»»

One of Bristol-Myers’s largest shareholders is opposing the company’s $74 billion deal to buy rival Celgene, becoming the latest investor to express its unhappiness with the transaction......»»

Bristol-Myers Squibb Co expressed disappointment on Thursday with the opposition of its top shareholder to a $74 billion takeover of Celgene Corp, and said it would press on with what would be the largest pharmaceutical acquisition of all time......»»

Activ.....»»

Activist investor Starboard Value LP will vote against Bristol-Myers Squibb Co's $74 billion acquisition of Celgene Corp, the hedge fund said on Thursday, adding to the number of shareholders declaring against the deal......»»

Activist investor Starboard Value LP plans to vote against Bristol-Myers Squibb Co's proposed $74 billion takeover of biotech Celgene Corp and urged other shareholders to join it in voting down the "poorly conceived and ill-advised" deal......»»

Activist hedge fund Starboard Value .....»»